摘要
目的探讨帕金森病(Parkinson’s disease,PD)患者血清成纤维细胞生长因子22(fibroblast growth factor22,FGF22)和CXC型趋化因子配体16(CXC chemokine ligand 16,CXCL16)水平检测对认知障碍的诊断价值。方法选取2022年6月~2023年6月邯郸市中医院收治的PD患者125例作为研究对象,并根据PD患者是否发生认知功能障碍,将其分为认知障碍未发生组(n=38)和认知障碍发生组(n=87)。采用酶联免疫吸附(ELISA)法测定各组血清FGF22,CXCL16水平。采用Spearman相关性分析血清FGF22,CXCL16表达水平与帕金森综合评分量表(unified Parkinson’s disease rating scale,UPDRS)及蒙特利尔认知评估量表(Montreal Cognitive assessment,MoCA)评分之间的相关性。采用多因素Logistic回归分析影响PD患者认知障碍的因素。采用受试者工作特征(ROC)曲线分析FGF22,CXCL16对PD患者认知障碍的诊断效能。结果相比于认知障碍未发生组,认知障碍发生组血清FGF22表达水平(184.16±14.62ng/ml vs 203.24±12.15ng/ml)显著降低(t=7.048),CXCL16表达水平显著升高(2.59±0.46ng/ml vs2.06±0.34ng/ml)(t=6.376),UPDRS评分(41.43±5.62分vs 32.46±4.28分)显著升高(t=8.782),MoCA评分(23.91±3.14分vs 26.54±2.31分)显著减低(t=4.640),差异具有统计学意义(均P<0.001)。根据Spaerman相关性分析得知,血清FGF22表达水平与UPDRS评分呈负相关(r=-0.435,P<0.05),与MoCA评分呈正相关(r=0.742,P<0.05);血清CXCL16表达水平与UPDRS评分呈正相关(r=0.532,P<0.05),与MoCA评分呈负相关(r=-0.623,P<0.05)。多因素Logistic分析显示,FGF22,MoCA评分是影响PD患者认知障碍的保护因素(P<0.05),CXCL16,UPDRS评分是影响PD患者认知障碍的危险因素(P<0.05);血清FGF22,CXCL16联合诊断PD患者认知障碍的AUC优于各自单独诊断(Z=2.919,2.437,P=0.003,0.015),敏感度和特异度分别为93.10%和73.68%。结论血清FGF22,CXCL16水平与PD患者认知障碍密切相关,两者联合可更好地诊断PD患者是否发生认知障碍。
Objective To explore the diagnostic value of serum levels of fibroblast growth factor 22(FGF22)and CXC chemokine ligand 16(CXCL16)in patients with Parkinson’s disease(PD)in cognitive impairment.Methods A total of 125 PD patients admitted to Handan Traditional Chinese Medicine Hospital from June 2022 to June 2023 were selected as the research subjects,and they were separated into a non cognitive impairment group(n=38)and a cognitive impairment group(n=87)based on whether they had cognitive impairment.Enzyme-linked immunosorbent assay(ELISA)was applied to determine the levels of serum FGF22 and CXCL16 in each group.Spearman correlation was applied to analyze the correlation among serum FGF22 and CXCL16 expression levels,Unified Parkinson’s Disease Rating Scale(UPDRS)and Montreal Cognitive Assessment(MoCA)scores.Multivariate logistic regression was applied to analyze the factors affecting cognitive impairment in PD patients.Receiver operating characteristic(ROC)curve was applied to analyze the diagnostic efficacy of FGF22 and CXCL16 for cognitive impairment in PD patients.Results Compared with the non cognitive impairment group,the expression level of serum FGF22(184.16±14.62ng/ml vs 203.24±12.15ng/ml)in cognitive impairment group and the MoCA score(23.91±3.14分vs 26.54±2.31分)were decreased(t=7.048,4.460,all P<0.05),while the expression levels of CXCL16(2.59±0.46ng/ml vs 2.06±0.34ng/ml)and the UPDRS score(41.43±5.62 score vs 32.46±4.28 score)were increased(t=6.376,8.782,all P<0.05),and the differences were statisaically significant.According to Spearman correlation analysis,the expression level of serum FGF22 was negatively correlated with UPDRS score(r=-0.435,P<0.05),but positively correlated with MoCA score(r=0.742,P<0.05).The expression level of CXCL16 in serum was positively correlated with UPDRS score(r=0.532,P<0.05),but negatively correlated with MoCA score(r=-0.623,P<0.05).Multivariate logistic analysis showed that FGF22 and MoCA scores were protective factors for cognitive impairment in PD pat
作者
牛荣荣
宋世雄
宋蕾
NIU Rongrong;SONG Shixiong;SONG Lei(Department 1 of Brain Disease,Handan Traditional Chinese Medicine Hospital,Hebei Handan 056000,China)
出处
《现代检验医学杂志》
CAS
2024年第3期152-156,193,共6页
Journal of Modern Laboratory Medicine
基金
河北省中医药管理局科研计划项目(2018393)。
